{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:06:18Z","timestamp":1763755578681,"version":"3.45.0"},"reference-count":31,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2014,6,1]]},"DOI":"10.1188\/14.cjon.330-337","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T21:51:53Z","timestamp":1401227513000},"page":"330-337","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing the Management of Patients With Myelofibrosis"],"prefix":"10.1188","volume":"18","author":[{"given":"Patricia J.","family":"Manea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2014,5,27]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","article-title":"Primary myelofibrosis: Update on definition, pathogenesis, and treatment","volume":"60","author":"O. Abdel-Wahab","year":"2009","journal-title":"Annual Review of Medicine"},{"key":"2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/jco.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European Leukemia Net","volume":"29","author":"T. Barbui","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"3","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.36","article-title":"How I treat splenomegaly in myelofibrosis","volume":"1","author":"F. Cervantes","year":"2011","journal-title":"Blood Cancer Journal"},{"key":"4","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"F. Cervantes","year":"2009","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cervantes, F., Kiladjian, J.J., Niederwieser, D., Sirulnik, A., Stalbovskaya, V., McQuity, M., \u2026 Harrison, C.N. (2012). Long-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [Abstract 801]. Retrieved from <a target=\"_blank\" href='http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/120\/21\/801'>http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/120\/21\/801<\/a>","DOI":"10.1182\/blood.V120.21.801.801"},{"key":"6","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"R. Emanuel","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/jco.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"N. Gangat","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"8","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3324\/haematol.2008.004234","article-title":"Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: A population-based study","volume":"94","author":"F. Girodon","year":"2009","journal-title":"Haematologica"},{"key":"9","first-page":"1","article-title":"Clinical and laboratory features of myelofibrosis and limitations of current therapies","volume":"9","author":"S. Gregory","year":"2011","journal-title":"Clinical Advances in Hematology Oncology"},{"key":"10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"C. Harrison","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"J. Mehta","year":"2014","journal-title":"Leukemia and Lymphoma"},{"key":"12","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"113","author":"R. Mesa","year":"2009","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/10428194.2012.710905","article-title":"The evolving treatment paradigm in myelofibrosis","volume":"54","author":"R. Mesa","year":"2013","journal-title":"Leukemia and Lymphoma"},{"key":"14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","article-title":"MPN-associated myelofibrosis (MPN-MF)","volume":"35","author":"R. Mesa","year":"2011","journal-title":"Leukemia Research"},{"key":"15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet-based survey of 1179 MPD patients","volume":"109","author":"R. Mesa","year":"2007","journal-title":"Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"R. Mesa","year":"2009","journal-title":"Leukemia Research"},{"key":"17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.leukres.2013.04.017","article-title":"Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study","volume":"37","author":"R. Mesa","year":"2013","journal-title":"Leukemia Research"},{"key":"18","first-page":"95","article-title":"Ruxolitinib for the treatment of myelofibrosis: Its clinical potential","volume":"8","author":"A. Ostojic","year":"2012","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"19","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"F. Passamonti","year":"2010","journal-title":"Blood"},{"key":"20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"A. Quintas-Cardama","year":"2011","journal-title":"Nature Reviews. Drug Discovery"},{"key":"21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/asheducation-2008.1.83","article-title":"From palliation to epigenetic therapy in myelofibrosis","author":"A. Rambaldi","year":"2008","journal-title":"Hematology\/The Education Program of the American Society of Hematology"},{"key":"22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients","volume":"118","author":"R. Scherber","year":"2011","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: The Mayo Clinic experience","volume":"87","author":"A. Tefferi","year":"2012","journal-title":"Mayo Clinic Proceedings"},{"key":"24","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"W. Vainchenker","year":"2011","journal-title":"Blood"},{"key":"25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1182\/asheducation-2011.1.222","article-title":"Management of myelofibrosis","author":"A. Vannucchi","year":"2011","journal-title":"Hematology\/The Education Program of the American Society of Hematology"},{"key":"26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"J. Vardiman","year":"2009","journal-title":"Blood"},{"key":"27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OTT.S53348","article-title":"Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes","volume":"7","author":"S. Verstovsek","year":"2013","journal-title":"OncoTargets and Therapy"},{"key":"28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"S. Verstovsek","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"29","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: Results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"S. Verstovsek","year":"2013a","journal-title":"Haematologica"},{"key":"30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, phase III study in patients with myelofibrosis","volume":"161","author":"S. Verstovsek","year":"2013b","journal-title":"British Journal of Haematology"},{"key":"31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/NCC.0b013e3182595406","article-title":"Therapy-related symptom checklist use during treatments at a cancer center","volume":"36","author":"P. Williams","year":"2012","journal-title":"Cancer Nursing"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/74271117K1X81104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:53:59Z","timestamp":1763754839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/18\/3\/optimizing-management-patients-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,27]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6,1]]}},"alternative-id":["74271117K1X81104"],"URL":"https:\/\/doi.org\/10.1188\/14.cjon.330-337","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2014,5,27]]}}}